GSK's Phase III B-Well trials show bepirovirsen achieved 19% functional cure in chronic hepatitis B, rising to 26% in patients with lower viral activity, versus 0% for placebo. Regulatory decisions are expected in Q3 2026.
January and March 2026 drug pipeline updates included Phase 3 results, Fast Track designations and Priority Review decisions across multiple disease areas. Mavacamten, teplizumab-mzwv, anifrolumab, AXS-05, gedatolisib and AFTX-201 were among the programs with notable milestones.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07696520 |
Bepirovirsen Liver Biopsy Study |
NOT_YET_RECRUITING | PHASE2 |
| NCT06537414 |
A Study of Sequential Therapy With Daplusiran/Tomligisiran (DAP/TOM) Followed by Bepirovirsen in Participants Living With Chronic Hepatitis B (CHB) |
ACTIVE_NOT_RECRUITING | PHASE2 |
| NCT06497504 |
Study of Bepirovirsen in Participants Living With Human Immunodeficiency Virus and Chronic Hepatitis B Virus Infection (B-Focus) |
ACTIVE_NOT_RECRUITING | PHASE2 |
| NCT06422767 |
Study to Evaluate the Effect of Bepirovirsen on Cardiac Conduction as Assessed by 12-lead Electrocardiogram in Healthy Volunteers |
COMPLETED | PHASE1 |
| NCT05630820 |
Study of Bepirovirsen in Nucleos(t)Ide Analogue-treated Participants With Chronic Hepatitis B (B-Well 2) |
COMPLETED | PHASE3 |
| NCT05630807 |
Study of Bepirovirsen in Nucleos(t)Ide Analogue-treated Participants With Chronic Hepatitis B (B-Well 1) |
COMPLETED | PHASE3 |
| NCT05330455 |
Study of GSK3965193 in Healthy Participants and Participants Living With Chronic Hepatitis B Infection |
TERMINATED | PHASE1/PHASE2 |
| NCT04954859 |
Long-term Follow-up Study to Evaluate Durability of Treatment Response in Previous Bepirovirsen Study Participants (B-Sure) |
ACTIVE_NOT_RECRUITING | PHASE2 |
